StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Down 0.5 %
Evoke Pharma stock opened at $4.29 on Friday. The stock has a 50-day simple moving average of $5.70 and a 200 day simple moving average of $6.26. Evoke Pharma has a 12-month low of $3.75 and a 12-month high of $18.60. The stock has a market capitalization of $3.13 million, a price-to-earnings ratio of -2.34 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The business had revenue of $2.55 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- 5 Top Rated Dividend Stocks to Consider
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What is the Australian Securities Exchange (ASX)
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
